Strategic IO Partnerships Matica Bio has established collaborations with Calidi Biotherapeutics, KaliVir Immunotherapeutics, CytoImmune Therapeutics, and Treovir, highlighting strong demand for viral vector manufacturing in oncology and pediatric gene therapies. This creates ready-made entry points for new partners in immuno-oncology and gene therapy seeking scalable CDMO support through development and manufacturing.

Credible CDMO Reputation Positioned as a go-to CDMO for cell and gene therapies, Matica Bio demonstrates credibility in enabling accelerated clinical timelines and reliable manufacturing. Use this reputation to engage early-stage programs that need a trusted partner with quality and regulatory alignment.

End-to-End Manufacturing Offers end-to-end manufacturing using state-of-the-art single-use bioreactors and remote monitoring, reinforced by ISO 13485 quality systems. This combination is attractive to firms seeking faster development-to-production with strong oversight and compliance.

Pediatric & Brain Therapies Collaborations covering pediatric blister and ulcer therapies and pediatric brain tumor treatment indicate a niche in pediatric gene therapies. Target biotech teams pursuing pediatric indications requiring safe, scalable viral vector manufacturing.

Leadership & Growth Appointment of a Chief Commercial Officer signals a focused push on strategic partnerships and business development. Leverage leadership to discuss co-development, capacity expansion, or long-term manufacturing arrangements with growth-stage gene therapy programs.